ArticleGynecologic oncology2023

Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.

William A Zammarrelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.